secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK:        0001314052
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001731122-24-000758
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anavex Q2 FY2024 net loss $10.5M, cash $139.4M; blarcamesine EMA submission underway
--------------------------------------------------------------------------------

- Net loss of $10.5M ($0.13/share) vs $13.1M loss ($0.17/share) in prior-year quarter.
- Cash and equivalents $139.4M at Mar 31, 2024; estimated ~4-year runway at current burn rate.
- R&D expenses $9.7M, G&A $2.8M; no revenue as clinical-stage biopharma.
- Marketing Authorisation application for blarcamesine (Alzheimer's) submitted to EMA; FDA guidance supports single cognitive endpoint.
- First cohort fully enrolled in ANAVEX3-71 Phase 2 schizophrenia trial; Phase 2b/3 Alzheimer's data to be published.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314052/000173112224000758/0001731122-24-000758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314052/000173112224000758/e5655_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-24-000758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer